SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-009351
Filing Date
2022-04-15
Accepted
2022-04-15 16:41:54
Documents
15
Period of Report
2022-04-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20220415.htm   iXBRL 8-K 47247
2 EX-1.1 ex11salesagreement.htm EX-1.1 285259
3 EX-5.1 ex51opinion8-k.htm EX-5.1 10101
7 image_0a.jpg GRAPHIC 18321
  Complete submission text file 0001628280-22-009351.txt   566716

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20220415.xsd EX-101.SCH 1905
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20220415_lab.xml EX-101.LAB 24844
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20220415_pre.xml EX-101.PRE 13045
9 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20220415_htm.xml XML 11523
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 22830417
SIC: 2834 Pharmaceutical Preparations